Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions
2006 | journal article; research paper. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Sättler, Muriel B., Iris Demmer, Sarah K. Williams, Katharina Maier, Doron Merkler, Ivana Gadjanski, Christine Stadelmann, Mathias Bähr, and Ricarda Diem. "Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions." Experimental Neurology 201, no. 1 (2006): 172-181. https://doi.org/10.1016/j.expneurol.2006.04.015.
Documents & Media
Details
- Authors
- Sättler, Muriel B. ; Demmer, Iris ; Williams, Sarah K.; Maier, Katharina ; Merkler, Doron ; Gadjanski, Ivana ; Stadelmann, Christine ; Bähr, Mathias ; Diem, Ricarda
- Abstract
- lntcrferon-beta-1a (IFN-beta-1a) is an approved treatment for multiple sclerosis (MS). It improves the disease course by reducing the relapse rate as well as the persistent neurological deficits. Recent MRI and post-mortem studies revealed that neuronal and axonal damage are most relevant for chronic disability in MS patients. We have characterized previously time course and mechanisms of neuronal apoptosis in a rat model of myelin oligodendrocyte glycoprotein (MOG)-induced optic neuritis. In this animal model, application of IFN-beta-1a three times per week slightly decreases the loss of retinal ganglion cells (RGCs), the neurons that form the axons within the optic nerve. In contrast to neurotrophic factors, this cytokine does not directly protect cultured RGCs from apoptosis. We conclude that IFN-beta-1a is a suitable candidate to be combined with a directly neuroprotective agent in order to further decrease axonal and neuronal degeneration in MS patients. (c) 2006 Elsevier Inc. All rights reserved.
- Issue Date
- 2006
- Journal
- Experimental Neurology
- ISSN
- 0014-4886
- Language
- English